Italia markets closed

NuCana plc (N04A.F)

Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,56500,0000 (0,00%)
Alla chiusura: 09:49AM CEST
Schermo intero
Chiusura precedente0,5650
Denaro0,5650 x 0
Lettera0,5700 x 0
Min-Max giorno0,5650 - 0,5650
Intervallo di 52 settimane0,5600 - 2,9000
Media Volume221
Beta (5 anni mensile)0,58
Rapporto PE (ttm)N/D
EPS (ttm)-0,9170
Prossima data utili17 ago 2022 - 22 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A751,02
  • GlobeNewswire

    NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update

    Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Initiate Randomized Phase 2 Study for NUC-3373 in Colorectal Cancer Extends Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, April 27, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2021 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

  • GlobeNewswire

    NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022

    Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro NUC-3373 Shown to be a More Efficient DNA Damaging Agent in Cancer Cells than 5-FU NUC-3373 Did Not Generate Metabolites Associated with 5-FU Dose-Limiting Toxicities EDINBURGH, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the release of two abstracts to be presented as posters at the American Association of Cancer Research (AACR) Annual Meeting being held from April 8 to 13, 2022. Abs

  • GlobeNewswire

    NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

    Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373 Continues Rapid Development with Multiple Data Readouts and Dosing of First Patients in Phase 3 Colorectal Cancer Study Expected in 2022 NUC-7738 Entering Phase 2 Solid Tumor and Lymphoma Study with Data Readouts Expected Throughout 2022 EDINBURGH, United Kingdom, March 02, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the NuTide:1